TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39078682

Group type: EXPERIMENTAL
Intervention: DART assessment
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Adjusted DART analysis
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: System Usability Scale
Number of subjects: 78

Group type: COMPARATOR
Intervention: Physiotherapist triage
Number of subjects: 78
Study: 39078687

Group type: EXPERIMENTAL
Intervention: Digital somatosensory dance game training (two 30-minute sessions per week for 6 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy aging education (control group)
Number of subjects: 60
Study: 39078712

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 0
Study: 39078826

Group type: EXPERIMENTAL
Intervention: Personalized food-derived resistant starches as an adjuvant therapy
Number of subjects: 42
Study: 39078857

Group type: EXPERIMENTAL
Intervention: Automated ventilation (INTELLiVENT-Adaptive Support Ventilation)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Automated ventilation (INTELLiVENT-Adaptive Support Ventilation) in passive patients
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional ventilation in passive patients
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Automated ventilation (INTELLiVENT-Adaptive Support Ventilation) in active patients
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional ventilation in active patients
Number of subjects: 96
Study: 39079071

Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing (WGS) from participants with ALS Reversal, n = 22
Number of subjects: 22

Group type: COMPARATOR
Intervention: Whole-genome sequencing (WGS) from the PGB primary cohort, n = 103
Number of subjects: 22

Group type: COMPARATOR
Intervention: Whole-genome sequencing (WGS) from the Target ALS validation cohort, n = 140
Number of subjects: 22
Study: 39079108

Group type: EXPERIMENTAL
Intervention: mPRISM (mobile app version of Promoting Resilience in Stress Management)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 80
Study: 39079110

Group type: EXPERIMENTAL
Intervention: Mandatory and promoted use of step tracker mobile app (10 weeks)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Nonmandatory and nonpromoted use of step tracker mobile app (10 weeks)
Number of subjects: 357
Study: 39079111

Group type: EXPERIMENTAL
Intervention: Extreme Gradient Boosting (XGBoost) model for predicting all-cause in-hospital mortality.
Number of subjects: 30762

Group type: COMPARATOR
Intervention: Global Registry of Acute Coronary Events (GRACE) model.
Number of subjects: 30762

Group type: COMPARATOR
Intervention: TIMI model.
Number of subjects: 30762

Group type: EXPERIMENTAL
Intervention: XGBoost model validated on China PEACE cohort.
Number of subjects: 30762
Study: 39079163

Group type: EXPERIMENTAL
Intervention: pegcetacoplan
Number of subjects: 25
Study: 39079406

Group type: EXPERIMENTAL
Intervention: First-episode schizophrenia (FES) patients
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ultra-high-risk (UHR) individuals
Number of subjects: 75

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 75
Study: 39079612

Group type: EXPERIMENTAL
Intervention: 24-week intensive multi-component physical activity intervention combining a wearable physical activity tracker, social media peer support group, and individualized goal setting followed by a 24-week maintenance phase
Number of subjects: 384

Group type: COMPARATOR
Intervention: Wearable physical activity tracker only (control group)
Number of subjects: 384
Study: 39079614

Group type: EXPERIMENTAL
Intervention: FBT+ER (Family-based treatment with emotion regulation)
Number of subjects: 166

Group type: COMPARATOR
Intervention: FBT (Standard Family-based treatment)
Number of subjects: 166
Study: 39079754

Group type: EXPERIMENTAL
Intervention: Tear break-up time (TBUT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schirmer test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conjunctival staining
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corneal staining
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meibomian gland dysfunction (MGD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tear osmolarity
Number of subjects: 0
Study: 39079894

Group type: EXPERIMENTAL
Intervention: Abatacept treatment
Number of subjects: 778

Group type: COMPARATOR
Intervention: Active Conventional Treatment (ACT)
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Biological treatments (including certolizumab pegol and tocilizumab)
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: ACPA, RF and SE allele-related genotypes
Number of subjects: 778
Study: 39079918

Group type: EXPERIMENTAL
Intervention: Interval life events reported during follow-ups
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Perceived stress score (PSS-4)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Interval life events
Number of subjects: 330
Study: 39079921

Group type: EXPERIMENTAL
Intervention: Postoperative whole breast irradiation combined with regional lymph node irradiation (RNI) following breast-conserving surgery or chest wall irradiation with RNI after mastectomy
Number of subjects: 0
Study: 39079925

Group type: EXPERIMENTAL
Intervention: Acupuncture and usual care (n=125)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual care alone (n=125)
Number of subjects: 250
Study: 39079926

Group type: EXPERIMENTAL
Intervention: Integrated evidence-based physical therapy (I-EPT) with mindfulness-based interventions
Number of subjects: 90

Group type: COMPARATOR
Intervention: High-intensity training (HighIT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Low-intensity training (LowIT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No training
Number of subjects: 90
Study: 39079927

Group type: EXPERIMENTAL
Intervention: Dichoptic balanced binocular viewing (BBV) for 1 hour a day for 16 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard management (part-time occlusion or atropine blurring) for 16 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dichoptic balanced binocular viewing (BBV)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard management (part-time occlusion or atropine blurring)
Number of subjects: 32
Study: 39079928

Group type: EXPERIMENTAL
Intervention: Mitapivat
Number of subjects: 0
Study: 39080091

Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Number of subjects: 1132

Group type: COMPARATOR
Intervention: Non-oxaliplatin
Number of subjects: 1132
Study: 39080094

Group type: EXPERIMENTAL
Intervention: Conners, CPT-3 d' T-score
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CPT-3 d' T-score ≥ 60 (clinically significant poor performance)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Sensory responsiveness profiles
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Impact on sleep, quality of life, anxiety, and depressive symptoms
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Overall attention problems
Number of subjects: 44
Study: 39080153

Group type: EXPERIMENTAL
Intervention: Deucravacitinib 6 mg once daily
Number of subjects: 1686

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1686

Group type: COMPARATOR
Intervention: Apremilast 30 mg twice daily
Number of subjects: 1686
Study: 39080181

Group type: EXPERIMENTAL
Intervention: Stapokibart 600 mg loading dose, then 300 mg every 2 weeks for 52 weeks
Number of subjects: 127
Study: 39080350

Group type: EXPERIMENTAL
Intervention: Dactinomycin and Vincristine (AV) chemotherapy
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Dactinomycin and Vincristine (AV) chemotherapy for bilateral stage I patients
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Nephron-sparing surgery (NSS)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Overall survival and renal function
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Overall estimated 5y-EFS for BWT
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Overall estimated 5y-EFS for unilateral WT and contralateral nephroblastomatosis
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Overall estimated 5y-EFS for bilateral nephroblastomatosis
Number of subjects: 327
Study: 39080364

Group type: EXPERIMENTAL
Intervention: Repositionable self-expanding valves
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repositioning during TAVR
Number of subjects: 0
Study: 39080380

Group type: EXPERIMENTAL
Intervention: Cuffs Inflated group (CI group, n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cuffs Collapsed group (CC group, n=30)
Number of subjects: 60
Study: 39080417

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 25
Study: 39080545

Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thoracic Paravertebral Block (TPVB)
Number of subjects: 40
Study: 39080666

Group type: EXPERIMENTAL
Intervention: GEMS-H exoskeleton in assistance mode
Number of subjects: 41
Study: 39080698

Group type: EXPERIMENTAL
Intervention: Early percutaneous screw fixation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conservative management (early mobilization under physiotherapy and analgesics)
Number of subjects: 68
Study: 39080734

Group type: EXPERIMENTAL
Intervention: Guided home exercise telehealth intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Center-based exercise intervention
Number of subjects: 0
Study: 39080741

Group type: EXPERIMENTAL
Intervention: DLB patients
Number of subjects: 84

Group type: COMPARATOR
Intervention: Healthy Elderly Controls
Number of subjects: 84

Group type: COMPARATOR
Intervention: Alzheimer's Disease patients
Number of subjects: 84
Study: 39081141

Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to Daily Occupational Performance (CO-OP) intervention, 12 sessions (2 sessions per week, 1 hour each, over 6 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 30
Study: 39081460

Group type: EXPERIMENTAL
Intervention: Prior TBI
Number of subjects: 405

Group type: COMPARATOR
Intervention: No prior TBI
Number of subjects: 405
Study: 39081632

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Neonatal vaccination
Number of subjects: 796
Study: 39081682

Group type: EXPERIMENTAL
Intervention: No-added-sugar ice cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional ice cream
Number of subjects: 0
Study: 39081738

Group type: EXPERIMENTAL
Intervention: Lumasiran (36 months of treatment)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (30 months of lumasiran treatment)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Lumasiran treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Lumasiran and Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Lumasiran
Number of subjects: 39
Study: 39081746

Group type: EXPERIMENTAL
Intervention: Regional-adjusted model for predicting reduced kidney function
Number of subjects: 14180

Group type: COMPARATOR
Intervention: UK model without regional adjustment
Number of subjects: 14180
Study: 39081763

Group type: EXPERIMENTAL
Intervention: Once weekly semaglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39081837

Group type: EXPERIMENTAL
Intervention: SLBT (Single Leg Balance Test)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SRT (Sit-to-Stand Test)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30CST (30-Second Chair Stand Test)
Number of subjects: 0
Study: 39081982

Group type: EXPERIMENTAL
Intervention: BPSDiary intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 300
Study: 39082399

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (ARNI) therapy
Number of subjects: 63
Study: 39082405

Group type: EXPERIMENTAL
Intervention: HF-SMA (Shared Medical Appointments)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Usual-care
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: HF-SMA
Number of subjects: 242
Study: 39082406

Group type: EXPERIMENTAL
Intervention: Cardiovascular polypill (2 Polycaps taken orally once a day for 12 months, containing aspirin 100mg, simvastatin 20mg, hydrochlorothiazide 12.5mg, ramipril 5mg, and atenolol 50mg)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Usual care (standard secondary prevention therapy)
Number of subjects: 148
Study: 39082415

Group type: EXPERIMENTAL
Intervention: High plasma putrescine levels
Number of subjects: 3570

Group type: EXPERIMENTAL
Intervention: High plasma spermidine and spermine levels
Number of subjects: 3570

Group type: EXPERIMENTAL
Intervention: Composite outcome of death and major disability (modified Rankin Scale score≥3)
Number of subjects: 3570
Study: 39082421

Group type: EXPERIMENTAL
Intervention: Mental stress testing
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Pharmacological stress testing
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Exercise stress testing
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Holter testing
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Psychological assessments
Number of subjects: 84
Study: 39082426

Group type: EXPERIMENTAL
Intervention: MyStroke personalized educational platform
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard stroke education
Number of subjects: 120
Study: 39082471

Group type: COMPARATOR
Intervention: Calcium channel blockers (CCBs)
Number of subjects: 8706

Group type: COMPARATOR
Intervention: Angiotensin receptor blockers (ARB)
Number of subjects: 8706

Group type: COMPARATOR
Intervention: ACE inhibitors (ACEi)
Number of subjects: 8706

Group type: COMPARATOR
Intervention: Dual therapy, alpha-blockers, and mineralocorticoid receptor antagonists
Number of subjects: 8706
Study: 39082668

Group type: EXPERIMENTAL
Intervention: Venetoclax-obinutuzumab (Ven-Obi)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Chlorambucil-obinutuzumab (Clb-Obi)
Number of subjects: 432
Study: 39082675

Group type: EXPERIMENTAL
Intervention: MIRV plus bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bevacizumab alone
Number of subjects: 0
Study: 39082730

Group type: EXPERIMENTAL
Intervention: LAAO
Number of subjects: 1020
Study: 39082735

Group type: EXPERIMENTAL
Intervention: V116
Number of subjects: 717
Study: 39082803

Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI) of meropenem
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intermittent infusion (II) of meropenem
Number of subjects: 16
Study: 39083005

Group type: EXPERIMENTAL
Intervention: WeChat WeQuit training program
Number of subjects: 1887

Group type: COMPARATOR
Intervention: Control group (thanks messages)
Number of subjects: 1887
Study: 39083052

Group type: EXPERIMENTAL
Intervention: Pregnancy pilates-assisted birth preparation training (twice a week for 8 weeks)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Pregnancy pilates-assisted birth preparation training
Number of subjects: 126
Study: 39083105

Group type: EXPERIMENTAL
Intervention: Intraventricular radioimmunotherapy (RIT) with 925-1850 MBq (25-50 mCi) of radiolabeled antibody
Number of subjects: 0
Study: 39083099

Group type: EXPERIMENTAL
Intervention: VACStent treatment for anastomotic leak (AL) without stoma placement
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: VACStent treatment for anastomotic leak (AL) after stoma placement
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prophylactic VACStent applications for high-risk anastomoses
Number of subjects: 12
Study: 39083147

Group type: EXPERIMENTAL
Intervention: faricimab 6.0 mg every 8 weeks (Q8W)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: faricimab treat-and-extend (T&E)
Number of subjects: 60

Group type: COMPARATOR
Intervention: aflibercept 2.0 mg every 8 weeks (Q8W)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: faricimab (both Q8W and T&E)
Number of subjects: 60

Group type: COMPARATOR
Intervention: aflibercept
Number of subjects: 60
Study: 39083185

Group type: EXPERIMENTAL
Intervention: Narrow-diameter implants with immediate provisionalization
Number of subjects: 77
Study: 39083200

Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 30
Study: 39083288

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 16 weeks
Number of subjects: 822

Group type: COMPARATOR
Intervention: Guselkumab 100 mg every 8 weeks
Number of subjects: 822
Study: 39083323

Group type: EXPERIMENTAL
Intervention: HER2-targeted PET/CT imaging before anti-HER2 therapy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: HER2-targeted PET/CT imaging
Number of subjects: 59
Study: 39083331

Group type: EXPERIMENTAL
Intervention: SMS text message reminder on the 14th day of kit pick up
Number of subjects: 9369

Group type: COMPARATOR
Intervention: No reminder (control group)
Number of subjects: 9369

Group type: EXPERIMENTAL
Intervention: SMS text message reminder
Number of subjects: 9369
Study: 39083340

Group type: EXPERIMENTAL
Intervention: Health coach-led, asynchronous, text-based digital behavior change coaching intervention (DBCCI)
Number of subjects: 107
Study: 39083478

Group type: EXPERIMENTAL
Intervention: Group interpersonal synchrony intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group non-synchronous intervention
Number of subjects: 0
Study: 39083494

Group type: EXPERIMENTAL
Intervention: Walking aid group (A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Walking aid and telemonitoring group (B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 0
Study: 39083526

Group type: EXPERIMENTAL
Intervention: Galvanic vestibular stimulation (GVS) for 2 weeks
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sham group (noneffective stimulation)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Galvanic vestibular stimulation (GVS) for healthy controls
Number of subjects: 75
Study: 39083587

Group type: EXPERIMENTAL
Intervention: AS01-adjuvanted vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alum-adjuvanted vaccine
Number of subjects: 0
Study: 39083724

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) 10 mg/kg once on days 1 and 8 every 3 weeks
Number of subjects: 41
Study: 39083792

Group type: EXPERIMENTAL
Intervention: Telerehabilitation (TR) administered via a web-based application, 1-hour sessions weekly for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care (UC) with home exercises provided on paper, 1-hour sessions weekly for 4 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clinic+TR group with in-person sessions and web-based platform for home exercises, 1-hour sessions weekly for 4 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TR-only group with virtual sessions and web-based platform for home exercises, 1-hour sessions weekly for 4 weeks
Number of subjects: 20
Study: 39083801

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) data with 5%-50% data loss
Number of subjects: 84

Group type: COMPARATOR
Intervention: Continuous Glucose Monitoring (CGM) data without data loss
Number of subjects: 84
Study: 39084177

Group type: EXPERIMENTAL
Intervention: Partial clinical remission (pCR) defined as stimulated C-peptide >300 pmol/l
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Partial clinical remission (pCR) defined as insulin dose-adjusted HbA1c ≤9%
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Partial clinical remission (pCR) defined as insulin dose <0.3 IU/kg/24 h and HbA1c ≤6.4% (46 mmol/mol)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Partial clinical remission (pCR) defined as insulin dose <0.5 IU/kg/24 h and HbA1c <7% (53 mmol/mol)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Combination of age, HbA1c, diastolic blood pressure, triglycerides and smoking at T1D onset
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: HbA1c, triglycerides and insulin dose 3-months post-diagnosis
Number of subjects: 133
Study: 39084489

Group type: EXPERIMENTAL
Intervention: KT-474, a targeted degrader of IRAK4, ex vivo treatment of PBMCs from healthy volunteers and patients with HS.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: KT-474, ex vivo treatment of toll-like receptor-stimulated healthy donor monocytes.
Number of subjects: 30

Group type: COMPARATOR
Intervention: HS lesional skin samples compared to nonlesional tissue.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HS lesional skin samples.
Number of subjects: 30
Study: 39084517

Group type: EXPERIMENTAL
Intervention: HIV-adapted and personally tailored decision aid
Number of subjects: 40
Study: 39084707

Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39084827

Group type: EXPERIMENTAL
Intervention: Jewel patch-wearable cardioverter-defibrillator (P-WCD)
Number of subjects: 305
Study: 39084829

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 41

Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 41
Study: 39084863

Group type: EXPERIMENTAL
Intervention: Healthy mutation carriers (HMC) with elevated t-tau (>290 pg/mL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Symptomatic gCJD patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy relatives (non-carriers)
Number of subjects: 60
Study: 39084935

Group type: EXPERIMENTAL
Intervention: Random forest algorithm for predicting PD-L1 expression and immunotherapy prognosis
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Random forest model predicting treatment response in PD-L1 high-expression patients
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Random forest model predicting improved survival in PD-L1 high-expression patients
Number of subjects: 204
Study: 39085080

Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg once daily for up to 6 or 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg once daily for up to 6 or 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vonoprazan in patients aged <65 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vonoprazan in current smokers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vonoprazan in the Chinese subpopulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lansoprazole in the Chinese subpopulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vonoprazan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lansoprazole
Number of subjects: 0